{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T17:47:36Z","timestamp":1791308856958,"version":"4.3.1"},"reference-count":27,"publisher":"Elsevier BV","issue":"13","license":[{"start":{"date-parts":[[2010,3,1]],"date-time":"2010-03-01T00:00:00Z","timestamp":1267401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2010,3]]},"DOI":"10.1016\/j.vaccine.2010.01.029","type":"journal-article","created":{"date-parts":[[2010,2,1]],"date-time":"2010-02-01T07:02:36Z","timestamp":1265007756000},"page":"2565-2572","source":"Crossref","is-referenced-by-count":134,"title":["Phase 1 clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5 hemagglutinin"],"prefix":"10.1016","volume":"28","author":[{"given":"Larry R.","family":"Smith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary K.","family":"Wloch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luane R.","family":"Reyes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Souphaphone","family":"Boutsaboualoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Casey E.","family":"Dunne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer A.","family":"Chaplin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Rusalov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain P.","family":"Rolland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy L.","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed S.","family":"Al-Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin L.","family":"Kabongo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy","family":"Steigbigel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert B.","family":"Belshe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernest R.","family":"Kitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice H.","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald B.","family":"Moss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2010.01.029_bib1","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1056\/NEJMra0707279","article-title":"Update on avian influenza A (H5N1) virus infection in humans","volume":"358","author":"Abdel-Ghafar","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2010.01.029_bib2","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/S0140-6736(06)68656-X","article-title":"Safety and immunogenicity of an inactivated split-virion influenza A\/Vietnam\/1194\/2004 (H5N1) vaccine: phase I randomised trial","volume":"367","author":"Bresson","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2010.01.029_bib3","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1086\/592172","article-title":"Safety and immunogenicity of an inactivated influenza A\/H5N1 vaccine given with or without aluminum hydroxide to healthy adults: results of a phase I\u2013II randomized clinical trial","volume":"198","author":"Keitel","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2010.01.029_bib4","doi-asserted-by":"crossref","first-page":"4160","DOI":"10.1016\/j.vaccine.2008.05.077","article-title":"Phase I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in healthy adults","volume":"26","author":"Nolan","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2010.01.029_bib5","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1056\/NEJMoa055778","article-title":"Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine","volume":"354","author":"Treanor","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2010.01.029_bib6","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1086\/527489","article-title":"Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults","volume":"197","author":"Bernstein","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2010.01.029_bib7","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1056\/NEJMoa073121","article-title":"A clinical trial of a whole-virus H5N1 vaccine derived from cell culture","volume":"358","author":"Ehrlich","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2010.01.029_bib8","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/S0140-6736(07)61297-5","article-title":"Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial","volume":"370","author":"Leroux-Roels","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2010.01.029_bib9","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1086\/590913","article-title":"An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults","volume":"198","author":"Levie","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2010.01.029_bib10","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.coph.2007.06.004","article-title":"Preparing for a possible pandemic: influenza A\/H5N1 vaccine development","volume":"7","author":"Keitel","year":"2007","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.vaccine.2010.01.029_bib11","doi-asserted-by":"crossref","first-page":"796","DOI":"10.3201\/eid0805.010476","article-title":"DNA vaccine expressing conserved influenza virus proteins protective against H5N1 challenge infection in mice","volume":"8","author":"Epstein","year":"2002","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2010.01.029_bib12","doi-asserted-by":"crossref","first-page":"157","DOI":"10.4161\/hv.3.5.4175","article-title":"Vaxfectin-formulated influenza DNA vaccines encoding NP and M2 viral proteins protect mice against lethal viral challenge","volume":"3","author":"Jimenez","year":"2007","journal-title":"Hum Vaccin"},{"key":"10.1016\/j.vaccine.2010.01.029_bib13","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1086\/588431","article-title":"Plasmid DNA-based vaccines protect mice and ferrets against lethal challenge with A\/Vietnam\/1203\/04 (H5N1) influenza virus","volume":"197","author":"Lalor","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2010.01.029_bib14","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/13484","article-title":"A universal influenza A vaccine based on the extracellular domain of the M2 protein","volume":"5","author":"Neirynck","year":"1999","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2010.01.029_bib15","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1126\/science.8456302","article-title":"Heterologous protection against influenza by injection of DNA encoding a viral protein","volume":"259","author":"Ulmer","year":"1993","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2010.01.029_bib16","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1016\/S0264-410X(00)00445-X","article-title":"Vaxfectin enhances the humoral immune response to plasmid DNA-encoded antigens","volume":"19","author":"Hartikka","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2010.01.029_bib17","doi-asserted-by":"crossref","first-page":"3778","DOI":"10.1016\/S0264-410X(01)00090-1","article-title":"Vaxfectin enhances antigen specific antibody titers and maintains Th1 type immune responses to plasmid DNA immunization","volume":"19","author":"Reyes","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2010.01.029_bib18","first-page":"1","article-title":"General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"55","author":"Kroger","year":"2006","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.vaccine.2010.01.029_bib19","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.virusres.2004.02.019","article-title":"Detection of anti-H5 responses in human sera by HI using horse erythrocytes following MF59-adjuvanted influenza A\/Duck\/Singapore\/97 vaccine","volume":"103","author":"Stephenson","year":"2004","journal-title":"Virus Res"},{"key":"10.1016\/j.vaccine.2010.01.029_bib20","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1128\/JCM.37.4.937-943.1999","article-title":"Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays","volume":"37","author":"Rowe","year":"1999","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2010.01.029_bib21","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1086\/588385","article-title":"Safety and immunogenicity of a bivalent cytomegalovirus DNA vaccine in healthy adult subjects","volume":"197","author":"Wloch","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2010.01.029_bib22","first-page":"3478","article-title":"Memory T cells established by seasonal human influenza A infection cross-react with avian influenza A (H5N1) in healthy individuals","volume":"118","author":"Lee","year":"2008","journal-title":"J Clin Invest"},{"key":"10.1016\/j.vaccine.2010.01.029_bib23","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1016\/j.vaccine.2008.02.068","article-title":"Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a phase III safety trial","volume":"26","author":"Rumke","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2010.01.029_bib24","unstructured":"FDA. Guidance for industry clinical data needed to support the licensure of pandemic influenza vaccines; 2007. Available at: http:\/\/www.fda.gov\/BiologicsBloodVaccines\/GuidanceComplianceRegulatoryInformation\/Guidances\/Vaccines\/ucm074770.htm [accessed October 8, 2009]."},{"key":"10.1016\/j.vaccine.2010.01.029_bib25","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1086\/498980","article-title":"Prior H1N1 influenza infection and susceptibility of Cleveland Family Study participants during the H2N2 pandemic of 1957: an experiment of nature","volume":"193","author":"Epstein","year":"2006","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2010.01.029_bib26","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1056\/NEJMe0903995","article-title":"Implications of the emergence of a novel H1 influenza virus","volume":"360","author":"Belshe","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2010.01.029_bib27","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1016\/S0264-410X(03)00071-9","article-title":"The annual production cycle for influenza vaccine","volume":"21","author":"Gerdil","year":"2003","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X10000617?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X10000617?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,27]],"date-time":"2020-05-27T05:24:45Z","timestamp":1590557085000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X10000617"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3]]},"references-count":27,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2010,3]]}},"alternative-id":["S0264410X10000617"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2010.01.029","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2010,3]]}}}